These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 26830552

  • 1. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S.
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 5. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J, Zheng X, Zhang W, Yang H.
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [Abstract] [Full Text] [Related]

  • 6. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, Rodari G, Filopanti M, Ferrante E, Spada A, Mantovani G.
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [Abstract] [Full Text] [Related]

  • 7. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
    Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Karavitaki N.
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.
    N Engl J Med; 2003 Nov 20; 349(21):2023-33. PubMed ID: 14627787
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
    Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS.
    Clin Endocrinol (Oxf); 2005 Jul 20; 63(1):26-31. PubMed ID: 15963057
    [Abstract] [Full Text] [Related]

  • 13. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO, Lu VM, Izzo A, De Biase G, Vilanilam G, Van Gompel JJ, Bernet V, Donaldson A, Olomu O, Meyer FB, Quinones-Hinojosa A, Chaichana KL.
    World Neurosurg; 2019 Sep 20; 129():e686-e694. PubMed ID: 31181361
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Women with prolactinomas presented at the postmenopausal period.
    Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A.
    Endocrine; 2014 Dec 20; 47(3):889-94. PubMed ID: 24711223
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov 20; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.